Revenue
2018
2019
2020
2021
2022
2023
2024
2025
IRONWOOD PHARMACEUTICALS INC (IRWD)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296.2M | $351.4M | $442.7M | $410.6M | $413.8M | $389.5M | $428.4M | $346.6M | $298.3M | $274.0M | $149.6M | $76.4M | $22.9M | $150.2M | $65.9M | $43.9M | $34.3M |
| Research & development | $95.1M | $111.4M | $116.1M | $44.3M | $70.4M | $88.1M | $115.0M | $101.1M | $88.1M | $139.5M | $108.7M | $101.9M | $102.4M | $113.5M | $86.1M | $77.5M | $76.1M |
| Operating expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $132.0M | $104.6M | $95.1M |
| Operating income | $98.5M | $93.1M | −$945.4M | $250.3M | $232.3M | $142.9M | $120.1M | −$150.7M | −$15.4M | −$51.9M | −$102.1M | −$169.4M | −$252.0M | −$72.8M | −$66.1M | −$60.8M | −$60.8M |
| EBITDAderived | $99.6M | $94.3M | −$944.2M | $251.7M | $233.8M | $145.2M | $125.7M | −$146.8M | −$9.0M | −$41.6M | −$90.5M | −$157.0M | −$240.3M | −$61.4M | −$56.1M | −$54.6M | −$56.1M |
| Net income | $24.0M | $880,000 | −$1.00B | $175.1M | $528.4M | $106.2M | $21.5M | −$282.4M | −$116.9M | −$81.7M | −$142.7M | — | — | −$72.6M | −$64.9M | −$51.9M | −$73.3M |
| Basic EPSper diluted share | $0.15 | $0.01 | -$6.45 | $1.13 | $3.26 | $0.67 | $0.14 | -$1.85 | -$0.78 | -$0.56 | -$1.00 | -$1.39 | -$2.35 | -$0.68 | -$0.65 | -$0.59 | -$10.00 |
| Diluted EPSper diluted share | $0.15 | $0.01 | -$6.45 | $0.96 | $3.21 | $0.66 | $0.14 | -$1.85 | -$0.78 | -$0.56 | -$1.00 | -$1.39 | -$2.35 | -$0.68 | -$0.65 | -$0.59 | -$10.00 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 16, 2026Form 4 · 10b5-1 | McHugh JulieDirector | SellClass A Common Stock | 21.6K | $3.73 | $80.5K | 250.7K |
| Mar 17, 2026Form 4 | DENNER ALEXANDER JDirector | SellClass A Common Stock · indirect | 5.8K | $3.31 | $19.2K | 9.19M |
| Mar 17, 2026Form 4 | DENNER ALEXANDER JDirector | SellClass A Common Stock · indirect | 6.72M | $3.05 | $20.51M | 9.19M |
| Feb 24, 2026Form 4 | Martini Gregory S.Chief Financial Officer | SellClass A Common Stock | 11.5K | $3.66 | $41.9K | 160.6K |
| Feb 24, 2026Form 4 | John MinardoChief Legal Officer | SellClass A Common Stock | 19.1K | $3.66 | $69.7K | 363.9K |